IP Library › Granted Patent US 11,187,709
Granted Patent B2
US 11,187,709 · App. 16/671,242 · Granted Nov 30, 2021

Release reagent for vitamin D compounds

Inventors: Sascha Antoni (Penzberg, DE); Christian Vogl (Bichl, DE)
Assignee: Roche Diagnostics Operations, Inc.
G01N33/82C07C401/00Y10T436/203332
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,187,709
App. No.
16/671,242
Granted
Nov 30, 2021
Kind
B2
Abstract

A reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein and an in vitro method for the detection of a vitamin D compound in which the vitamin D compound is released from vitamin D-binding protein by the use of this reagent composition as well as the reagent mixture obtained in this manner. Also disclosed is the use of the reagent compositions to release vitamin D compounds as well as a kit for detecting a vitamin D compound.

Claims (14)

1. An in vitro method for releasing a vitamin D compound from vitamin D-binding protein comprising the step of:

a) providing a sample to be investigated, wherein the sample comprises the vitamin D compound and the vitamin D-binding protein, and

b) mixing the sample from step (a) with

i) a reagent containing about 0.1 M to about 2.0 M of one or more hydrogen carbonate salt(s) and one or more carbonate ester(s),

ii) a reducing agent, and

iii) an alkalinising agent,

wherein upon mixing, HCO 3 − is released from the one or more hydrogen carbonate salt(s) and the one or more carbonate ester(s) at a total concentration ranging from 0.1 M to 2.0 M and the vitamin D compound is released from the vitamin D-binding protein.

2. The method according to claim 1 , wherein the reagent according to step (i) is soluble in an aqueous solution under appropriate conditions for releasing the vitamin D compound from the vitamin D-binding protein.

3. The method according to claim 1 , wherein the carbon ester(s) is selected from the group consisting of a cylic carbonate ester, a non-cyclic carbonate ester, a hydroxylated cyclic carbonate ester, a hydroxylated non-cyclic carbonate ester, a halogenized cyclic carbonate ester, and a halogenized non-cyclic carbonate ester.

4. The method according claim 1 , wherein the sample is a liquid sample.

5. The method according to claim 1 , wherein the sample is blood, serum or plasma.

6. An in vitro method for measuring a vitamin D compound comprising the steps of: a) releasing a vitamin D compound from a vitamin D-binding protein according to the method of claim 1 ; and b) measuring the vitamin D compound released in step (a).

7. The method according to claim 6 , wherein the vitamin D compound is selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D2, 24,25-dihydroxyvitamin D3 and C3-epi 25-hydroxyvitamin D.

8. The method according to claim 7 , wherein the vitamin D compounds 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3 are determined.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2019
From: ANTONI, SASCHA; VOGL, CHRISTIAN
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 051156/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2019
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 051156/0240 →
Priority Claims (1)
EP 11189736 · Nov 18, 2011 · regional
Continuity (6)
Continuation 15693903 · Sep 1, 2017
Continuation 15144172 · May 2, 2016
Continuation 14874702 · Oct 5, 2015
Continuation 14277359 · May 14, 2014
Continuation PCTEP2012072569 · Nov 14, 2012
Related Publication 20200072854A1 · Mar 5, 2020